Voyager Therapeutics, Inc. (NASDAQ:VYGR) Given Consensus Rating of “Moderate Buy” by Brokerages

Voyager Therapeutics, Inc. (NASDAQ:VYGR) has received an average recommendation of “Moderate Buy” from the six analysts that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation and five have given a buy recommendation to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $12.1460.

VYGR has been the subject of a number of research analyst reports. Weiss Ratings reissued a “sell (d)” rating on shares of Voyager Therapeutics in a report on Wednesday, October 8th. HC Wainwright reduced their price objective on Voyager Therapeutics from $30.00 to $25.00 and set a “buy” rating for the company in a research note on Wednesday, November 12th. Wedbush restated an “outperform” rating and issued a $8.00 price objective on shares of Voyager Therapeutics in a report on Tuesday, November 11th. Finally, Wall Street Zen raised shares of Voyager Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 15th.

Insider Transactions at Voyager Therapeutics

In other Voyager Therapeutics news, CFO Nathan D. Jorgensen sold 7,666 shares of the stock in a transaction dated Friday, October 3rd. The shares were sold at an average price of $4.78, for a total value of $36,643.48. Following the completion of the sale, the chief financial officer owned 123,834 shares in the company, valued at approximately $591,926.52. This represents a 5.83% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 4.53% of the company’s stock.

Institutional Investors Weigh In On Voyager Therapeutics

A number of large investors have recently made changes to their positions in VYGR. Privium Fund Management B.V. raised its stake in shares of Voyager Therapeutics by 16.6% in the 2nd quarter. Privium Fund Management B.V. now owns 25,241 shares of the company’s stock valued at $79,000 after acquiring an additional 3,596 shares during the period. American Century Companies Inc. lifted its stake in Voyager Therapeutics by 5.1% during the second quarter. American Century Companies Inc. now owns 138,269 shares of the company’s stock worth $430,000 after purchasing an additional 6,748 shares in the last quarter. Jain Global LLC boosted its position in shares of Voyager Therapeutics by 44.1% during the third quarter. Jain Global LLC now owns 28,104 shares of the company’s stock worth $131,000 after buying an additional 8,600 shares during the period. AXQ Capital LP grew its stake in shares of Voyager Therapeutics by 47.8% in the third quarter. AXQ Capital LP now owns 27,360 shares of the company’s stock valued at $128,000 after buying an additional 8,844 shares in the last quarter. Finally, Wexford Capital LP purchased a new stake in shares of Voyager Therapeutics in the 3rd quarter valued at $42,000. 48.03% of the stock is currently owned by hedge funds and other institutional investors.

Voyager Therapeutics Stock Performance

Voyager Therapeutics stock opened at $3.95 on Tuesday. The stock has a market capitalization of $219.62 million, a P/E ratio of -1.83 and a beta of 1.24. The company’s fifty day moving average price is $4.51 and its 200 day moving average price is $3.79. Voyager Therapeutics has a 1 year low of $2.64 and a 1 year high of $7.44.

Voyager Therapeutics (NASDAQ:VYGR) last announced its earnings results on Monday, November 10th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.53) by $0.06. The business had revenue of $11.15 million for the quarter, compared to analyst estimates of $7.86 million. Voyager Therapeutics had a negative net margin of 404.85% and a negative return on equity of 48.94%. Sell-side analysts predict that Voyager Therapeutics will post -0.91 EPS for the current year.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.